Year Founded
2018
Ownership
Private
Employees
~50
Stage
Phase 3
Modalities
Small molecule

Arthrosi Therapeutics General Information

Lead compound AR882 demonstrated unprecedented sustained urate lowering in gout patients in Phase 2b trials. Currently conducting two parallel Phase 3 trials (REDUCE 1 and REDUCE 2) for gout and tophaceous gout treatment.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

AR882
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Arthrosi Therapeutics's pipeline data

Book a demo

Key Partnerships

ApicHope Pharmaceuticals

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Arthrosi Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCJan 26, 2024$7.0MCompletedPhase 3
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Arthrosi Therapeutics's complete valuation and funding history, request access »

Arthrosi Therapeutics Investors

Raised $75 million in Series D financing in July 2023; total raised $135.72 million
Investor Type: Venture Capital
Holding: Minority